Search by property

This page provides a simple browsing interface for finding entities described by a property and a named value. Other available search interfaces include the page property search, and the ask query builder.

List of results

• Reference:EU EMA/431265/2016 Annex I – to guidance for the conduct of good clinical practice inspections – investigator site 06-Sep-2017 4.  + (TAG-00032-Inf-ngs ++ TAG-00343-Doc-ten ++ TAG-00150-Sou-eUr ++ TAG-00112-Ass-nve ++ TAG-00029-Inf-rte)
• Reference:EU EMA/INS/GCP/143492/2022 - ANNEX I TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE CHMP: INVESTIGATOR SITE 2022 Page 6  + (TAG-00032-Inf-ngs ++ TAG-00343-Doc-ten ++ TAG-00150-Sou-eUr ++ TAG-00112-Ass-nve ++ TAG-00029-Inf-rte)
• Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 Appendix 2  + (TAG-00033-Pro-oto)
• Reference:WHO WHO - HANDBOOK FOR GOOD CLINICAL RESEARCH PRACTICE (GCP) 2005 Page 28-29  + (TAG-00033-Pro-oto)
• Reference:EU ENCePP - Guide on Methodological Standards in Pharmacoepidemiology Revision 11 (2023) 3  + (TAG-00033-Pro-oto)
• Reference:DEU DGEPi - GEP Guter Epidemiologischer Praxis Sep-2018 Leitlinie 3  + (TAG-00033-Pro-oto ++ TAG-00010-Non-Stu ++ TAG-00338-Met-odi)
• Reference:DEU DGEPi - GEP Guter Epidemiologischer Praxis Sep-2018 Leitlinie 3 3.10  + (TAG-00033-Pro-oto ++ TAG-00010-Non-Stu ++ TAG-00343-Doc-ten ++ TAG-00340-Req-nfo)
• Reference:USA 21 CFR Part 312 09-Apr-2025 § 312.23 (a) ; (6)  + (TAG-00033-Pro-oto ++ TAG-00011-Inv-tud ++ TAG-00320-Foo-eri ++ TAG-00340-Req-nfo)
• Reference:ICH ICH E6 Guideline R3 (2025) Appendix B 6-001  + (TAG-00033-Pro-oto ++ TAG-00025-Sub-mer ++ TAG-00287-Sto-pre ++ TAG-00246-Inv-hte ++ TAG-00011-Inv-tud)
• Reference:ICH ICH E6 Guideline R3 (2025) Appendix B 6-002  + (TAG-00033-Pro-oto ++ TAG-00025-Sub-mer ++ TAG-00287-Sto-pre ++ TAG-00246-Inv-hte ++ TAG-00011-Inv-tud)
• Reference:ICH ICH E6 Guideline R3 (2025) Appendix B  + (TAG-00033-Pro-oto ++ TAG-00041-Ame-run ++ TAG-00329-Saf-lne ++ TAG-00176-Ris-erh)
• Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 2  + (TAG-00033-Pro-oto ++ TAG-00041-Ame-run ++ TAG-00017-Spo-die ++ TAG-00246-Inv-hte)
• Reference:WMA Declaration of Helsinki 2024 Paragraph 22  + (TAG-00033-Pro-oto ++ TAG-00051-Eth-ngs ++ TAG-00176-Ris-erh ++ TAG-00340-Req-nfo)
• Reference:N.A. SPIRIT 2013 - Chan et al. 2013 -  + (TAG-00033-Pro-oto ++ TAG-00075-Pub-ich)
• Reference:ICH ICH E6 Guideline R3 (2025) II 7.4  + (TAG-00033-Pro-oto ++ TAG-00076-Fea-ung ++ TAG-00017-Spo-die ++ TAG-00317-Obj-set)
• Reference:ISO ISO 14155 - Clinical investigation of medical devices for human subjects 2020 Annex A A.6.3-001  + (TAG-00033-Pro-oto ++ TAG-00077-Inc-gsk ++ TAG-00078-Exc-ssk ++ TAG-00201-Cli-eSt ++ TAG-00086-Fol-Fol)
• Reference:ISO ISO 14155 - Clinical investigation of medical devices for human subjects 2020 Annex A A.6.3-002  + (TAG-00033-Pro-oto ++ TAG-00077-Inc-gsk ++ TAG-00078-Exc-ssk ++ TAG-00201-Cli-eSt ++ TAG-00086-Fol-Fol)
• Reference:EU Regulation (EU) 536/2014 - clinical trials 05-Dec-2022 ANNEX I Section D No. 17  + (TAG-00033-Pro-oto ++ TAG-00137-Mon-che ++ TAG-00113-Aud-tQu ++ TAG-00044-Ins-ion ++ TAG-00130-Dir-gDi)
• Reference:EU Regulation (EU) 536/2014 - clinical trials 05-Dec-2022 ANNEX I Section D No.17 ; No. 22  + (TAG-00033-Pro-oto ++ TAG-00145-Ran-ute ++ TAG-00123-Bli-ppe ++ TAG-00314-Unb-ung ++ TAG-00098-IMP-tik)
• Reference:WHO WHO - HANDBOOK FOR GOOD CLINICAL RESEARCH PRACTICE (GCP) 2005 Overview of the Clinical Research Process  + (TAG-00033-Pro-oto ++ TAG-00151-Sta-rat ++ TAG-00137-Mon-che ++ TAG-00134-Eth-kom ++ TAG-00135-Inv-ntr ++ TAG-00341-Res-ben)
• Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 Glossary - protocol  + (TAG-00033-Pro-oto ++ TAG-00244-Def-ini ++ TAG-00338-Met-odi ++ TAG-00317-Obj-set)
• Reference:ICH ICH E8 Guideline R1 (2021) 5.  + (TAG-00033-Pro-oto ++ TAG-00302-Ada-die ++ TAG-00055-Stu-ngs ++ TAG-00011-Inv-tud)
• Reference:ICH ICH E6 Guideline R3 (2025) Appendix B 8  + (TAG-00033-Pro-oto ++ TAG-00304-Pri-tSt ++ TAG-00133-Ind-rhe ++ TAG-00041-Ame-run)
• Reference:INT ISPE - GPP Revision 3 (2015) II.  + (TAG-00033-Pro-oto ++ TAG-00340-Req-nfo)
• Reference:ICH ICH E6 Guideline R3 (2025) Appendix B 14.3  + (TAG-00033-Pro-oto ++ TAG-00343-Doc-ten ++ TAG-00073-Arc-arc ++ TAG-00340-Req-nfo)

• Reference:ISO ISO 14155 - Clinical investigation of medical devices for human subjects 2020 Annex B  + (TAG-00034-Inv-Bro)

• Reference:USA 21 CFR Part 312 09-Apr-2025 § 312.23 (a) ; (5)  + (TAG-00034-Inv-Bro ++ TAG-00011-Inv-tud ++ TAG-00320-Foo-eri ++ TAG-00017-Spo-die)
• Reference:ICH ICH E6 Guideline R3 (2025) Appendix A 3.4  + (TAG-00034-Inv-Bro ++ TAG-00011-Inv-tud ++ TAG-00095-Sto-ung ++ TAG-00035-Man-odu)
• Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 Glossary - investigator’s brochure  + (TAG-00034-Inv-Bro ++ TAG-00244-Def-ini)
• Reference:ICH ICH E6 Guideline R3 (2025) GLOSSARY - Investigator’s Brochure (IB)  + (TAG-00034-Inv-Bro ++ TAG-00244-Def-ini ++ TAG-00204-Cli-tbe)
• Reference:ICH ICH E6 Guideline R3 (2025) Appendix A  + (TAG-00034-Inv-Bro ++ TAG-00340-Req-nfo)
• Reference:GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 Schedule 7 Part 2 2.  + (TAG-00035-Man-odu ++ TAG-00011-Inv-tud ++ TAG-00132-Goo-rst ++ TAG-00057-Com-deR)
• Reference:DEU MPDG - Medizinprodukterecht-Durchführungsgesetz 28-Jun-2022 § 31  + (TAG-00036-Sta-ung ++ TAG-00201-Cli-eSt ++ TAG-00053-Dev-las ++ TAG-00134-Eth-kom ++ TAG-00155-Med-Med)
• Reference:DEU MPDG - Medizinprodukterecht-Durchführungsgesetz 28-Jun-2022 § 31a  + (TAG-00036-Sta-ung ++ TAG-00231-Per-ung ++ TAG-00176-Ris-erh ++ TAG-00220-Inv-agn)
• Reference:EU Regulation (EU) 536/2014 - clinical trials 05-Dec-2022 Article 2 Paragraph 26 - 29  + (TAG-00037-End-ung ++ TAG-00038-Ear-tig ++ TAG-00244-Def-ini ++ TAG-00087-End-Pat)
• Reference:EU Regulation (EU) 536/2014 - clinical trials 05-Dec-2022 Article 37 Paragraph 1 – 7  + (TAG-00037-End-ung ++ TAG-00039-Tem-ung ++ TAG-00038-Ear-tig ++ TAG-00262-CTI-Kli ++ TAG-00017-Spo-die)
• Reference:GBR The Medical Devices Regulations 2002 11-Feb-2021 Article 16 (11)  + (TAG-00037-End-ung ++ TAG-00088-Clo-esu ++ TAG-00201-Cli-eSt ++ TAG-00181-Man-npr ++ TAG-00155-Med-Med)
• Reference:EU Regulation (EU) 2017/745 - Medical Device Regulation 20-Mar-2023 Article 77 Paragraph 4 – 5  + (TAG-00037-End-ung ++ TAG-00201-Cli-eSt ++ TAG-00017-Spo-die ++ TAG-00142-Mul-ent ++ TAG-00253-Rep-att)
• Reference:GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 Article 27  + (TAG-00037-End-ung ++ TAG-00253-Rep-att ++ TAG-00017-Spo-die ++ TAG-00134-Eth-kom ++ TAG-00057-Com-deR)
• Reference:GBR Directive 2001/20/EC 04-Apr-2001 Article 10 (c)  + (TAG-00037-End-ung ++ TAG-00253-Rep-att ++ TAG-00017-Spo-die ++ TAG-00134-Eth-kom ++ TAG-00057-Com-deR)
• Reference:EU Regulation (EU) 536/2014 - clinical trials 05-Dec-2022 Article 37 Paragraph 4  + (TAG-00037-End-ung ++ TAG-00274-Fin-Spo ++ TAG-00275-Lay-ndl ++ TAG-00264-Eud-lin ++ TAG-00017-Spo-die)
• Reference:GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 Schedule 3 Part 1 1. (p)  + (TAG-00037-End-ung ++ TAG-00287-Sto-pre ++ TAG-00134-Eth-kom ++ TAG-00343-Doc-ten ++ TAG-00033-Pro-oto)
• Reference:ISO ISO 14155 - Clinical investigation of medical devices for human subjects 2020 8.2  + (TAG-00038-Ear-tig ++ TAG-00039-Tem-ung ++ TAG-00201-Cli-eSt ++ TAG-00017-Spo-die ++ TAG-00133-Ind-rhe)
• Reference:ICH ICH E6 Guideline R3 (2025) III. Annex 1 2.6  + (TAG-00038-Ear-tig ++ TAG-00039-Tem-ung ++ TAG-00246-Inv-hte ++ TAG-00025-Sub-mer)
• Reference:EU Regulation (EU) 536/2014 - clinical trials 05-Dec-2022 Article 38  + (TAG-00038-Ear-tig ++ TAG-00039-Tem-ung ++ TAG-00329-Saf-lne ++ TAG-00177-Ben-koB ++ TAG-00262-CTI-Kli)
• Reference:ICH ICH E6 Guideline R3 (2025) III. Annex 1 3.17.1  + (TAG-00038-Ear-tig ++ TAG-00039-Tem-ung ++ TAG-00245-Spo-ten ++ TAG-00057-Com-deR)
• Reference:EU Regulation (EU) 2017/745 - Medical Device Regulation 20-Mar-2023 Article 77 Paragraph 1 – 3  + (TAG-00038-Ear-tig ++ TAG-00039-Tem-ung ++ TAG-00201-Cli-eSt ++ TAG-00017-Spo-die ++ TAG-00329-Saf-lne)
• Reference:USA 21 CFR Part 312 09-Apr-2025 § 312.56  + (TAG-00038-Ear-tig ++ TAG-00176-Ris-erh ++ TAG-00017-Spo-die ++ TAG-00134-Eth-kom ++ TAG-00320-Foo-eri)
• Reference:GBR Directive 93/42/EEC 11-Oct-2007 Article 15 6. - 7.-001  + (TAG-00038-Ear-tig ++ TAG-00201-Cli-eSt ++ TAG-00329-Saf-lne ++ TAG-00214-Ser-hei ++ TAG-00057-Com-deR)
• Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.3 (q)  + (TAG-00038-Ear-tig ++ TAG-00244-Def-ini ++ TAG-00155-Med-Med ++ TAG-00320-Foo-eri)
• Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 5.14  + (TAG-00038-Ear-tig ++ TAG-00245-Spo-ten ++ TAG-00134-Eth-kom ++ TAG-00057-Com-deR)